Paolo Innocenti
Lab and Project Manager
- Name
- Dr. P. Innocenti
- Telephone
- 071 5276592
- p.innocenti@biology.leidenuniv.nl
- ORCID iD
- 0009-0001-1882-410X
.
Supervisor
Lab and Project Manager
- Faculty of Science
- IBL
- Microbial Sciences
- Zhou Q., Fransen A., Innocenti P., Ram A.F.J. & Winde J.H. de (2026), Utilization and valorization of lignin and lignin-derived compounds by Pseudomonas putida KT2440: a new role for glutathione peroxidase, New Biotechnology 92: 1-11.
- Matheson E.J., Beekveld R.A.M. van, Innocenti P., Martin N.I., Weingarth M. & Cochrane S.A. (2025), Chemical diversification of polyprenyl quinones for mechanistic studies on menaquinone-binding peptide antibiotics, Chemical Science 16(30): 13629-13635.
- Lysenko V., Gao M., Sterk F.A.C., Innocenti P., Slingerland C.J. & Martin N.I. (2025), Design, synthesis, and antibacterial evaluation of rifampicin–siderophore conjugates, ACS infectious diseases 11(8): 2301-2309.
- Sugrue I., Ade C., O'Connor P.M., Daniel J.M., Innocenti P., Kirsch N., Martin N.I., Weindl G., Hill C., Schneider T. & Paul R.R. (2025), Trans-kingdom conservation of mechanism between bacterial actifensin and eukaryotic defensins, npj Antimicrobials and Resistance 3: 66.
- Verschoor J., Croese M.R.J., Lakemeier S.E., Mugge A., Burgers C.M.C., Innocenti P., Willemse J.J., Crooijmans M.E., Wezel G.P. van, Ram A.F.J. & Winde J.H. de (2024), Polyester degradation by soil bacteria: identification of conserved BHETase enzymes in Streptomyces, Communications Biology 7: 725.
- Gao M., Kotsogianni A.I., Skoulikopoulou F., Brüchle N.C., Innocenti P. & Martin N.I. (2024), Synthesis and evaluation of carbapenem/metallo‐β‐lactamase inhibitor conjugates, ChemMedChem 19(21): e202400302.
- Ludwig K.C., Puls J.S., Matos de Opitz C.L., Innocenti P., Daniel J.M., Bornikoel J., Aets M., Krannich S., Straetener J., Braitenbach D., Henrichfreise B., Sass P., Mueller A., Martin N.I., Brötz-Oesterhelt H., Kubitscheck U., Grein F. & Schneider T. (2024), The dual mode of antibacterial action of the synthetic small molecule DCAP involves lipid II binding, Journal of the American Chemical Society 146(36): 24855-24862.
- Spriano F., Sartori G., Sgrignani J., Barnabei L., Arribas A.J., Guala M., Del Amor A.M.C., Tomasso M.R., Tarantelli C., Cascione L., Golino G., Riveiro M.E., Bortollozzi R., Lupia A., Paduano F., Huguet S., Rezai K., Rinaldi A., Martheriti F., Ventura P., Guarda G., Costa G., Rocca R., Furlan A., Verdonk L.M., Innocenti P., Martin N.I., Viola G., Driessen C., Zucca E., Stathis A., Gahtory D., Nieuwboer M. van den, Bornhauser B., Alcaro S., Trapasso F., Cristobal S., Padrick S.B., Pazzi N., Cavalli F., Cavalli A., Gaudio E. & Bertoni F. (2024), A first-in-class Wiskott-Aldrich syndrome protein activator with anti-tumor activity in hematologic cancers, Haematologica 109(11): 3602-3614.
- Groesen E. van, Innocenti P. & Martin N.I. (2022), Recent advances in the development of semisynthetic glycopeptide antibiotics: 2014–2022, ACS infectious diseases 8(8): 1381-1407.
- Slingerland C.J., Wesseling C.M.J., Innocenti P., Westphal K.G.C., Masereeuw R. & Martin N.I. (2022), Synthesis and evaluation of polymyxins bearing reductively labile disulfide-linked lipids, Journal of Medicinal Chemistry 65(23): 15878-15892.
- Wade N., Wesseling C.M.J., Innocenti P., Slingerland C.J., Koningstein G.M., Luirink J. & Martin N.I. (2022), Synthesis and structure–activity studies of β-barrel assembly machine complex inhibitor MRL-494, ACS infectious diseases 8(11): 2242-2252.
- Gao Y., Haren M.J., Buijs N., Innocent I., Zhang Y., Sartini D., Campagna R., Emanuelli M., Parsons R.B., Jespers W., Gutiérrez-de-Terán H., Westen G.J.P. van & Martin N.I. (2021), Potent inhibition of nicotinamide N-Methyltransferase by alkene-linked bisubstrate mimics bearing electron deficient aromatics, Journal of Medicinal Chemistry 64(17): 12938-12963.
- Groesen E. van, Slingerland C.J., Innocenti P., Mihajlovic M., Masereeuw R. & Martin N.I. (2021), Vancomyxins: vancomycin-polymyxin nonapeptide conjugates that retain anti-gram-positive activity with enhanced potency against gram-negative strains, ACS infectious diseases 7(9): 2746–2754.